BRIEF-Cryolife Inc Expects Revenue In H2 2021 To Rise 7% - 10% On A Pro Forma Constant Currency Basis Versus H2 2019

Reuters

Jul 30, 2021

July 29 (Reuters) - CryoLife Inc :

* EXPECTS REVENUE IN H2 2021 TO RISE 7% - 10% ON A PRO FORMA CONSTANT CURRENCY BASIS VERSUS H2 2019

* CRYOLIFE REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS

* Q2 NON-GAAP EARNINGS PER SHARE $0.12

* Q2 LOSS PER SHARE $0.06

* SEES Q3 REVENUE $71 MILLION TO $73 MILLION

* Q2 REVENUE $76.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $71 MILLION

* Q2 EARNINGS PER SHARE ESTIMATE $-0.05 -- REFINITIV IBES DATA

* REVENUES FOR Q3 OF 2021 ARE EXPECTED TO BE BETWEEN $71.0 MILLION AND $73.0 MILLION

* Q3 REVENUE VIEW $73.6 MILLION -- REFINITIV IBES DATA

Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2155182646"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2155182646\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2155182646?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-07-30 06:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2155182646","market":"us","top_or_hot":-1,"title":"BRIEF-Cryolife Inc Expects Revenue In H2 2021 To Rise 7% - 10% On A Pro Forma Constant Currency Basis Versus H2 2019","media":"Reuters","content":"<html><body><p>July 29 (Reuters) - <a href=\"https://laohu8.com/S/CRY\">CryoLife Inc</a>   :</p><p>   * EXPECTS REVENUE IN H2 2021 TO RISE 7% - 10% ON A PRO FORMA CONSTANT CURRENCY BASIS VERSUS H2 2019</p><p>   * CRYOLIFE REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS</p><p>   * Q2 NON-GAAP EARNINGS PER SHARE $0.12</p><p>   * Q2 LOSS PER SHARE $0.06</p><p>   * SEES Q3 REVENUE $71 MILLION TO $73 MILLION</p><p>   * Q2 REVENUE $76.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $71 MILLION</p><p>   * Q2 EARNINGS PER SHARE ESTIMATE $-0.05 -- REFINITIV IBES DATA</p><p>   * REVENUES FOR Q3 OF 2021 ARE EXPECTED TO BE BETWEEN $71.0 MILLION AND $73.0 MILLION</p><p>   * Q3 REVENUE VIEW $73.6 MILLION -- REFINITIV IBES DATA</p><p> Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Cryolife Inc Expects Revenue In H2 2021 To Rise 7% - 10% On A Pro Forma Constant Currency Basis Versus H2 2019</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Cryolife Inc Expects Revenue In H2 2021 To Rise 7% - 10% On A Pro Forma Constant Currency Basis Versus H2 2019\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-30 06:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>July 29 (Reuters) - <a href=\"https://laohu8.com/S/CRY\">CryoLife Inc</a>   :</p><p>   * EXPECTS REVENUE IN H2 2021 TO RISE 7% - 10% ON A PRO FORMA CONSTANT CURRENCY BASIS VERSUS H2 2019</p><p>   * CRYOLIFE REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS</p><p>   * Q2 NON-GAAP EARNINGS PER SHARE $0.12</p><p>   * Q2 LOSS PER SHARE $0.06</p><p>   * SEES Q3 REVENUE $71 MILLION TO $73 MILLION</p><p>   * Q2 REVENUE $76.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $71 MILLION</p><p>   * Q2 EARNINGS PER SHARE ESTIMATE $-0.05 -- REFINITIV IBES DATA</p><p>   * REVENUES FOR Q3 OF 2021 ARE EXPECTED TO BE BETWEEN $71.0 MILLION AND $73.0 MILLION</p><p>   * Q3 REVENUE VIEW $73.6 MILLION -- REFINITIV IBES DATA</p><p> Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LHDX","symbol_name":"Lucira Health, Inc.","start_time":0,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2155182646","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2155182646","pubTimestamp":1627597687,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"July 29  - CryoLife Inc   :   * EXPECTS REVENUE IN H2 2021 TO RISE 7% - 10% ON A PRO FORMA CONSTANT CURRENCY BASIS VERSUS H2 2019   * CRYOLIFE REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS   * Q2 NON-GAAP EARNINGS PER SHARE $0.12   * Q2 LOSS PER SHARE $0.06   * SEES Q3 REVENUE $71 MILLION TO $73 MILLION   * Q2 REVENUE $76.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $71 MILLION   * Q2 EARNINGS PER SHARE ESTIMATE $-0.05 -- REFINITIV IBES DATA   * REVENUES FOR Q3 OF 2021 ARE EXPECTED TO BE BETWEEN ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"LHDX":"Lucira Health, Inc.","CGEM":"Cullinan Therapeutics","SANA":"Sana Biotechnology, Inc.","LABP":"Landos Biopharma, Inc."},"translate_title":"简讯-Cryolife Inc.预计2021年H2的收入按备考不变汇率计算将较2019年H2增长7%-10%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRY":0.9,"SANA":1,"LABP":1,"APR":1,"CGEM":1,"LHDX":1},"content_text":"July 29 (Reuters) - CryoLife Inc   :   * EXPECTS REVENUE IN H2 2021 TO RISE 7% - 10% ON A PRO FORMA CONSTANT CURRENCY BASIS VERSUS H2 2019   * CRYOLIFE REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS   * Q2 NON-GAAP EARNINGS PER SHARE $0.12   * Q2 LOSS PER SHARE $0.06   * SEES Q3 REVENUE $71 MILLION TO $73 MILLION   * Q2 REVENUE $76.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $71 MILLION   * Q2 EARNINGS PER SHARE ESTIMATE $-0.05 -- REFINITIV IBES DATA   * REVENUES FOR Q3 OF 2021 ARE EXPECTED TO BE BETWEEN $71.0 MILLION AND $73.0 MILLION   * Q3 REVENUE VIEW $73.6 MILLION -- REFINITIV IBES DATA Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}